#ES­MO22: Seagen builds case for Pad­cev-Keytru­da com­bo in front-line blad­der can­cer

PARIS — In Ju­ly, sand­wiched in the back-and-forth ru­mors on a po­ten­tial Mer­ck buy­out, Seagen post­ed a topline look at its Pad­cev-Keytru­da com­bo as a first-line ther­a­py for ad­vanced blad­der can­cer.

While the read­out was pos­i­tive, with an over­all re­sponse rate of 64.5% in the dif­fi­cult-to-treat pa­tient group — those with ad­vanced or metasta­t­ic urothe­lial can­cer who were in­el­i­gi­ble for cis­platin chemother­a­py — Seagen and its part­ner Astel­las left many ques­tions unan­swered.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER